Index of reports
> Cases with Candida Test Positive (18)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Mesna where reactions include candida test positive. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-18
Patient: female, weighing 13.1 kg (28.8 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
Indication: Sarcoma Metastatic
Vinorelbine Tartrate
Dosage: last dose prior to sae:20/jun/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Doxorubicin Hydrochloride
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Cyclophosphamide
Dosage: last dose prior to sae 23/jun/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Other drugs received by patient: Ondansetron; Levomepromazine; Moviprep; Fluconazole; Levomepromazine; Cotrim; Docusate; Ondansetron; Gentamicin; Morphine; Moviprep; Neupogen; Neupogen; Dihydrocodeine Bitartrate INJ; Acetaminophen; Ondansetron; Docusate; Docusate; Piperacillin and Tazobactam; Moviprep; Emollient Cream (Unk Ingredients); Ondansetron
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-13
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine and Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Avastin
Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Vinorelbine Tartrate
Dosage: last dose prior to sae:20/jun/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Cyclophosphamide
Dosage: last dose prior to sae 23/jun/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Ondansetron; Ondansetron; Gentamicin; Moviprep; Moviprep; Levomepromazine; Moviprep; Docusate; Cotrim; Docusate; Neupogen; Acetaminophen; Levomepromazine; Neupogen; Ondansetron; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Docusate; Morphine; Emollient Cream (Unk Ingredients)
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-06
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Cyclophosphamide
Dosage: last dose prior to sae 23/jun/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Vinorelbine Tartrate
Dosage: last dose prior to sae:20/jun/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Avastin
Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Other drugs received by patient: Ondansetron; Neupogen; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Levomepromazine; Docusate; Piperacillin and Tazobactam; Cotrim; Gentamicin; Ondansetron; Morphine; Moviprep; Emollient Cream (Unk Ingredients); Ondansetron; Docusate; Moviprep; Neupogen; Acetaminophen; Levomepromazine; Moviprep; Docusate
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-02
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Vinorelbine Tartrate
Dosage: last dose prior to sae 08/may/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Cyclophosphamide
Dosage: last dose prior to sae 06/06/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Avastin
Dosage: frequency: day 1, last dose prior to sae: 21/05/2012
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Other drugs received by patient: Ondansetron; Levomepromazine; Moviprep; Moviprep; Cotrim; Morphine; Docusate; Docusate; Gentamicin; Moviprep; Emollient Cream (Unk Ingredients); Acetaminophen; Ondansetron; Ondansetron; Fluconazole; Levomepromazine; Piperacillin and Tazobactam; Ondansetron; Neupogen; Dihydrocodeine Bitartrate INJ; Docusate; Neupogen
Possible Mesna side effects in female
Reported by a individual with unspecified qualification from United Kingdom on 2012-05-29
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Vinorelbine Tartrate
Dosage: last dose prior to sae 08/may/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Avastin
Dosage: frequency: day 1, last dose prior to sae: 08/jul/2012
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Cyclophosphamide
Dosage: last dose prior to sae 11/may/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Other drugs received by patient: Fluconazole; Acetaminophen; Docusate; Emollient Cream (Unk Ingredients); Ondansetron; Ondansetron; Docusate; Morphine; Moviprep; Moviprep; Neupogen; Gentamicin; Moviprep; Ondansetron; Levomepromazine; Cotrim; Neupogen; Ondansetron; Levomepromazine; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Docusate
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-02-14
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Other drugs received by patient: Ondansetron; Ondansetron; Fluconazole; Levomepromazine; Docusate; Docusate; Morphine; Neupogen; Emollient Cream (Unk Ingredients); Levomepromazine; Docusate; Neupogen; Ondansetron; Moviprep; Moviprep; Piperacillin and Tazobactam; Ondansetron; Paracetamol; Cotrim; Gentamicin; Dihydrocodeine Bitartrate INJ
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-01-18
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Other drugs received by patient: Acetaminophen; Ondansetron; Moviprep; Neupogen; Levomepromazine; Levomepromazine; Gentamicin; Emollient Cream (Unk Ingredients); Docusate; Piperacillin and Tazobactam; Morphine; Ondansetron; Neupogen; Ondansetron; Docusate; Moviprep; Ondansetron; Fluconazole; Docusate; Cotrim; Dihydrocodeine Bitartrate INJ
Possible Mesna side effects in female
Reported by a individual with unspecified qualification from United Kingdom on 2012-01-12
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, RED Blood Cell Count Decreased, Febrile Neutropenia, Platelet Count Decreased, Blood Sodium Decreased, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Doxorubicin Hydrochloride
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Levomepromazine; Levomepromazine; Docusate; Piperacillin and Tazobactam; Moviprep; Ondansetron; Neupogen; Neupogen; Cotrim; Ondansetron; Docusate; Docusate; Gentamicin; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Morphine; Acetaminophen; Ondansetron; Moviprep; Emollient Cream (Unk Ingredients)
Possible Mesna side effects in female
Reported by a individual with unspecified qualification from United Kingdom on 2012-01-10
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Haemoglobin Decreased, Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Blood Creatinine Increased, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Morphine; Moviprep; Ondansetron; Cotrim; Moviprep; Emollient Cream (Unk Ingredients); Dihydrocodeine Bitartrate INJ; Acetaminophen; Piperacillin and Tazobactam; Ondansetron; Fluconazole; Neupogen; Ondansetron; Docusate; Docusate; Neupogen; Ondansetron; Levomepromazine; Levomepromazine; Docusate; Gentamicin
Possible Mesna side effects in male
Reported by a physician from United States on 2011-12-23
Patient: male
Reactions: Vomiting, Pain, Tachycardia, Rhinorrhoea, Pyrexia, Irritability, Candida Test Positive, Neutropenic Infection, Escherichia Test Positive, Diarrhoea, Feeling Hot, Tachypnoea, Septic Shock, Cough, Infection
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Ifosfamide
Indication: Sarcoma
Start date: 2001-10-02
Cisplatin
Indication: Sarcoma
Start date: 2001-10-02
Methotrexate
Indication: Sarcoma
Start date: 2001-10-02
Doxorubicin HCL
Indication: Sarcoma
Start date: 2001-10-02
Trastuzumab
Dosage: over 90 minutes on day 1, every week for 37 weeks
Indication: Sarcoma
Start date: 2001-10-02
Mesna
Filgrastim
Dosage: then over 15 minutes at hours 8,11,14 post infosamide at 1.8 g/m2 over 4 hours daily for 5 days
Indication: Sarcoma
Start date: 2001-10-02
Leucovorin Calcium
Administration route: Oral
Indication: Sarcoma
Start date: 2001-10-02
Etoposide
Dosage: then over 15 minutes at hours 8,11,14 post infosamide at 1.8 g/m2 over 4 hours daily for 5 days
Indication: Sarcoma
Start date: 2001-10-02
Trastuzumab
Dosage: on day 1(loading dose)
Start date: 2001-10-02
Dexrazoxane Hydrochloride
Indication: Sarcoma
Start date: 2001-10-02
Mesna
Dosage: then over 15 minutes at hours 8,11,14 post infosamide at 1.8 g/m2 over 4 hours daily for 5 days
Indication: Sarcoma
Start date: 2001-10-02
Possible Mesna side effects in female
Reported by a individual with unspecified qualification from United Kingdom on 2011-12-08
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Other drugs received by patient: Acetaminophen; Cotrim; Moviprep; Docusate; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Morphine; Gentamicin; Neupogen; Emollient Cream (Unk Ingredients); Docusate; Neupogen; Ondansetron; Fluconazole; Levomepromazine; Levomepromazine; Ondansetron; Ondansetron; Ondansetron; Moviprep
Possible Mesna side effects in female
Reported by a individual with unspecified qualification from United Kingdom on 2011-12-07
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Fluconazole; Piperacillin and Tazobactam; Ondansetron HCL; Ondansetron HCL; Moviprep; Ondansetron HCL; Docusate; Neupogen; Emollient Cream (Unk Ingredients); Acetaminophen; Levomepromazine; Levomepromazine; Cotrim; Ondansetron HCL; Docusate; Moviprep; Dihydrocodeine Bitartrate INJ; Gentamicin; Morphine; Neupogen
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2011-12-05
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Acetaminophen; Emollient Cream (Unk Ingredients); Cotrim; Piperacillin and Tazobactam; Moviprep; Levomepromazine; Docusate; Gentamicin; Neupogen; Fluconazole; Ondansetron; Morphine; Ondansetron; Moviprep
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2011-11-29
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Other drugs received by patient: Ondansetron; Neupogen; Ondansetron; Fluconazole; Piperacillin and Tazobactam; Morphine; Moviprep; Emollient Cream (Unk Ingredients); Paracetamol; Cotrim; Gentamicin; Moviprep; Docusate; Levomepromazine
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2011-11-14
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Other drugs received by patient: Ondansetron; Docusate; Moviprep; Acetaminophen; Cotrim; Morphine; Emollient Cream (Unk Ingredients); Levomepromazine; Piperacillin and Tazobactam; Fluconazole; Gentamicin; Ondansetron; Moviprep; Neupogen
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2011-11-11
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Gentamicin; Levomepromazine; Moviprep; Emollient Cream (Unk Ingredients); Acetaminophen; Ondansetron; Moviprep; Fluconazole; Cotrim; Ondansetron; Docusate; Morphine; Neupogen; Piperacillin and Tazobactam
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2011-10-18
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Avastin
Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cycle last doseprior to sae: 30 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Acetaminophen; Cotrim; Neupogen; Levomepromazine; Ondansetron; Piperacillin and Tazobactam; Fluconazole; Gentamycin Sulfate; Ondansetron; Docusate; Morphine; Moviprep; Moviprep
Possible Mesna side effects in female
Reported by a individual with unspecified qualification from United Kingdom on 2011-10-05
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 09 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cycle last doseprior to sae: 30 aug 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Doxorubicin Hydrochloride
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Avastin
Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Gentamycin Sulfate; Piperacillin and Tazobactam; Ondansetron; Ondansetron; Morphine; Acetaminophen; Fluconazole; Levomepromazine; Cotrim; Moviprep; Docusate; Moviprep; Neupogen
|